McDermott + Bull has successfully placed Courtney Darby as Head of Global Health Economics and Market Access at JenaValve Technology. In her new role, Courtney will lead strategies for global market access, fostering payor relationships, and managing coding and coverage, aiming to boost the adoption of JenaValve’s medical solutions.
Courtney has deep experience in the technology and healthcare space, most recently at Edwards Lifesciences where she oversaw the transcatheter mitral and tricuspid therapies, executing global reimbursement and market access strategies.
JenaValve is a medical device company specializing in innovative transcatheter heart valve technology, primarily for minimally invasive treatment of aortic regurgitation (AR). Their flagship product, the JenaValve Trilogy Heart Valve System, is the only device approved in the EU for treating severe AR in high-risk patients and is also approved for aortic stenosis treatment. In the US, JenaValve has completed a pivotal trial for the Trilogy System, aiming for future approval as the first TAVR system for severe AR treatment. The company is based in Irvine, California, with additional offices in the U.K. and Germany.
This executive search was completed by McDermott + Bull Partner Ken Dropiewski, Director Shelby Varon, and Research Associate Michael Matranga.